Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Onconetix, Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on men's health and oncology diagnostics. Registration statements, amendments, proxy materials, and current reports describe securities offerings, preferred stock and warrant terms, common-stock structure, shareholder voting matters, and reverse-stock-split authorizations.
The company's SEC reports also disclose governance changes, board and executive appointments, material agreements, operating and financial results, clinical or regulatory matters, and risk factors related to its commercial-stage biotechnology business and Proclarix prostate cancer diagnostic.
Onconetix, Inc. filed Amendment No. 1 to its Form S-1 registration statement, mainly to add a new legal opinion as Exhibit 5.1 from Ellenoff Grossman & Schole LLP regarding the legality of the securities being registered. The amendment is described as an exhibit-only filing, with the remainder of the registration statement unchanged and omitted from this document.
The filing states that the proposed sale of securities may occur from time to time after the registration statement becomes effective. It also lists extensive corporate, financing, equity plan, and commercial agreements as exhibits and is signed on behalf of Onconetix by Chief Executive Officer David A. White and other directors and officers.
Onconetix, Inc. filed a Post-Effective Amendment No. 1 on Form S-1 to register 38,769,702 shares of Common Stock for resale by selling stockholders, consisting of shares issuable upon adjustment and exercise of previously issued Series D and Series E warrants. The registration covers resale only; the company will receive cash proceeds only if the warrants are exercised for cash. The prospectus discloses a one-for-five reverse stock split effective March 25, 2026, recent Series D/E PIPE financings, a pending Share Exchange Agreement to acquire Realbotix subject to customary closing conditions and a disclosed going concern risk with cash of $5.2M as of December 31, 2025 and approximately $4.0M as of May 4, 2026.
Onconetix, Inc. held a special meeting of stockholders on April 30, 2026, where stockholders approved a reverse stock split proposal and an adjournment proposal. Voting was based on 3,464,686 shares of common stock outstanding as of March 13, 2026, the record date.
The reverse stock split proposal received 1,301,918 votes for, 253,378 against and 1,393 abstentions. The adjournment proposal received 1,332,088 votes for, 223,071 against and 1,530 abstentions, meaning both items on the agenda were approved.
Onconetix, Inc. files an S-1 registering 25,000,000 shares of common stock for resale by Keystone Capital Partners under an equity line of credit. The company is not selling these shares itself but may receive up to $25.0 million as it issues stock to Keystone.
Through April 24, 2026, Onconetix sold about 701,933 split-adjusted shares under the equity line for roughly $8.1 million. As of December 31, 2025, it reported cash of about $5.2 million, a working capital deficit of roughly $3.1 million, and an accumulated deficit near $131.2 million, leading auditors to raise substantial doubt about its ability to continue as a going concern.
The filing also highlights a pending Share Exchange Agreement with Realbotix that could give Realbotix’s owner 75%–90% of fully diluted shares depending on Onconetix’s net cash at closing, implying major future dilution alongside existing PIPE financings and a recent one-for-five reverse stock split.
Onconetix, Inc. announced multiple board changes. Effective April 20, 2026, directors Andrew Oakley and Thomas Meier resigned from the board and their committee roles. Their departures were stated as not resulting from any disagreement with management or the board on company matters.
On April 23, 2026, existing director Sammy Dorf was appointed Chairman of the Board and will receive an additional $20,000 per year, paid quarterly, for this role. The board also elected Josh Epstein as a Class II director and member of the Audit Committee and Compensation Committee, and chair of the Nominating and Corporate Governance Committee, with a term running until the 2026 annual meeting of stockholders.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported an open-market sale of 49,710 Class A Shares at $0.69 per share. After this transaction, HRT Financial LP directly holds 33,649 Class A Shares of Onconetix.
This Form 4 reflects a net reduction in HRT Financial LP’s position, with no derivative securities reported as remaining holdings in this filing.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported several open-market trades in Class A Shares. On April 16, 2026 and April 20, 2026 it sold a total of 148,329 shares at about $0.73–$0.75 per share, and on April 17, 2026 it purchased 34,636 shares at $0.73. Overall, this was a net sale of 113,693 shares, leaving HRT Financial LP with 83,359 Class A Shares held directly after the last reported transaction.
Onconetix, Inc. major holder HRT FINANCIAL LP increased its stake with open-market purchases of Class A Shares. The investor bought 92,554 shares at $0.76 per share on April 15, 2026 and 74,350 shares at $0.77 per share on April 14, 2026. After these transactions, HRT FINANCIAL LP directly holds 197,052 Class A Shares, reflecting net buying activity over the two days.
Onconetix, Inc. disclosed that HRT FINANCIAL LP is a ten percent owner and filed an initial ownership report. The filing shows HRT FINANCIAL LP directly holds 104,498 Class A Shares of Onconetix common equity. This is a status report of existing holdings, not a new purchase or sale.